Accuracy is everything when patient lives are at stake
- >99.92% sensitivity / >99.99% specificity (1)
- Technological innovations, several unique to Myriad, have been developed over 20 years with 2.5 million patients tested
Myriad’s myVision™ Variant Classification program is considered the gold standard in the industry
- We employ over 30 medical professionals of varying disciplines who meet daily to classify and reclassify variants
- We use 8 published and peer-reviewed methodologies, 2 unique to Myriad that have >99% PPV or NPV (2,3,4)
- We classified over 10,000 variants in 2016, and sent over 400 reclassified results to providers every week
- Lifetime commitment to classification: We will provide you and your patients an updated result if a variant is reclassified, no matter when the original testing occurred
Responsible Stewards of the data
- Myriad is committed to protecting patient privacy and does not engage in activities that could compromise the privacy of an individual patient’s genetic information
- Myriad will always share an individual patient’s genetic test results with the patient, their provider and anyone else the patient designates access to
- Myriad shares data in a responsible fashion that respects patient privacy through peer-reviewed literature and scientific presentation, and is a founding member of the PROMPT registry
- In a responsible effort to share data, Myriad has contributed more to the scientific literature via publication and presentation than any other hereditary cancer lab
What to know when discussing test results with patients:
- A genetic mutation was found in 1 or more of the genes tested
- The patient is at increased risk for cancer
- A summary of medical management guidelines will be provided specific to the patient’s gene mutation(s)
- No genetic mutation was found in the genes tested
- The patient is at elevated risk for cancer based on an analysis of additional genetic markers, personal clinical risk factors, and/or their family’s history of cancer
- A summary of medical management guidelines will be provided based on the patient’s elevated risk
- No genetic mutation was found in the genes tested
- The common causes of hereditary cancer have been ruled out, but depending on family history of cancer, increased risks could still remain
- Depending on their family history, medical management is usually based on general population screening guidelines; however, discussion with your patient can determine if there are any changes in medical management that are most appropriate for them
Variant of uncertain significance
- A change in a gene has been identified
- It is not yet known if the change is associated with increased cancer risk
- Medical management based on personal and family history of cancer until more is understood about the specific change
If you are a woman, you may also receive a riskScore® result and/or a Tyrer-Cuzick breast cancer risk estimate.
riskScore is a breast cancer risk prediction result that provides women, who are unaffected by breast cancer, with a personalized calculation of their future breast cancer risk. riskScore results uses a combination of genetic markers and clinical factors in it’s calculation.
Tyrer-Cuzick is a breast cancer risk model used to predict a woman’s risk of developing breast cancer. The Tyrer-Cuzick model takes into consideration family history of cancer and other personal clinical risk factors.
If your remaining lifetime breast cancer risk is calculated to be 20% or greater with Tyrer-Cuzick or riskScore, a summary of medical management guidelines will be provided.
Elevate your practice with a personalized approach to cancer risk
Partner myRisk testing with riskScore™
- riskScore provides a personalized 5-year and remaining lifetime breast cancer risk calculation
- riskScore improves the predictive value of a negative genetic test with more precise information for breast cancer risk assessment and management
- riskscore provides personalized results for women who are negative for a genetic mutation associated with hereditary breast cancer
Myriad has developed and validated riskScore, a breast cancer prediction model that calculates 5-year and remaining lifetime risk of breast cancer. myRisk is enhanced with riskScore and the results will include the multi-gene hereditary cancer panel, a clinical and cancer history analysis and riskScore which is calculated using clinical risk factors and multiple genetic markers.
Partnering Myriad myRisk® with riskScore will help manage your patient’s personalized risk with the myRisk Medical Management Tool.
What is the myRisk Medical Management Tool?
The myRisk Medical Management Tool provides a summary of recent management recommendations from leading medical societies that you and your patients may consider. In general, changes to a patient’s management can take four possible directions:
- You may be recommended to screen a patient more often and perhaps with different or additional tests than they have had previously
- It might also be recommended that the patient take medications (known as risk-reducing agents) to reduce their risk
- There may be surgical procedures to consider
- You may discuss lifestyle changes with your patient
READY TO ORDER?
myRisk is easy to order
- First, identify patients at risk for hereditary cancer
- Second, fill out the Test Request Form (TRF)
- Third, collect sample from Myriad myRisk buccal collection kit or blood collection
- Last, receive results in your practice 7-14 day turn-around-time
- Judkins T et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer. 2014
- Pruss D et al. Development and validations of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes; Breast Cancer Research and Treatment. 2013
- Morris B et al. Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm; BMC Genetics. 2016
- Bowles K et al. Reclassification of uncertain variants in high and moderate cancer risk genes using history weighting analysis; ACMG. 2016